5,6-Dihydro-5'-azacytidine (DHAC) affects estrogen sensitivity in estrogen-refractory human breast carcinoma cell lines

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1293-1298

  Izbicka, Elzbieta ^a   Davidson, Karen K ^a   Lawrence, Richard A ^a   Macdonald, John R ^b   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

^b GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

Breast cancer; DHAC; Estrogen receptor; Estrogen sensitivity; Methylation

Indexed keywords

5,6 DIHYDROAZACITIDINE; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL COUNT; CELL GROWTH; CELL STIMULATION; CONTROLLED STUDY; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; AZACITIDINE; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SITE-SPECIFIC DNA METHYLTRANSFERASE (CYTOSINE-SPECIFIC); TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0033065813     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. McGuire W: Hormone receptors: their role in predicting prognosis and response to hormone therapy. Semin Oncol 5: 428-433, 1978.
2. Jones PA: DNA methylation errors and cancer. Cancer Res 56: 2463-2467, 1996.
3. Ottaviano YL, Issas JP, Parl FF, Smith HS, Baylin SB and Davidson NE: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54: 2552-2555, 1994.
4. Ferguson AT, Lapidus RG, Baylin SB and Davidson NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55: 2279-2283, 1995.
5. Harmon D, Vogelzang N, Roboz J, Goutsou M, Antman K, Coughlin K and Green MR: Dihydro-5-azacytidine (DHAC) in malignant mesothelioma (Meso) using serum hyaluronic acid (SHA) as tumor marker: a Phase II trial of the CALGB. ASCO Proc 10: 351, 1991.
6. Mossman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
7. Vogelzang NJ, Hamdon JE, Harmon DC, Antman KN, Carson JM, Suzuki Y, Citron ML and Green MR: Dihydro-5-azacytidine in malignant mesothelioma. Cancer 79: 2237-2242, 1997.
8. Murphy C, Parker C, McCague R and Jordan V: Structure-activity relationships of nonisomerable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Mol. Pharmacol 39: 421-428, 1991.
9. Loser, R., Seibel, K., and Eppenberger, U.: No loss of estrogenic and anitestrogenic activity after demethylation of drolixifene (3-OH-tamoxifen). Int J Cancer 36: 701-703, 1985.
10. Loser R, Seibel K, Roos W and Eppenberger U: In vivo and in vitro antoestrogenic action of 3-hydroxytamixifen, tamoxifen, and 4-hydroxytamoxifen. Eur J Cancer Clin Oncol 21: 985-990, 1985.
11. Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S and JA G: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925-5930, 1996.
12. Paech K, Webb P, Kuiper G, Nilsson S, Gustaffson J, Kushner P and Scanlan T: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1507-1510, 1997.
13. Gallo M and Kaufman D: Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin Oncol 24: SI71-S180, 1997.
14. Lindner, D. and Borden, E.: Synergistic antitumor effects of a combination of interferon and tamoxifen in estrogen receptor-positive and receptor-negative human tumor cells in vivo and in vitro. J Interferon Cytokine Res 17: 681-693, 1997.
15. Coradini D, Cappelletti V, Granata G and Di Fronzo G: Activity of tamoxifen and its metabolites on endocrine-dependent and endocrine-independent breast cancer cells. Tumour Biol 12: 149-158, 1991.
16. Gabbara S and Bhagwat A: The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem J 307: 87-92, 1995.
17. Izbicka E, Davidson K, Yoneda T, Williams P and Von Hoff DD: Cytidine analogs upregulate androgen receptor expression and induce apoptosis in human prostate cancer cells in vitro. J Bone Miner Res 11: 483, 1966.
18. Momparleur R, Bouffard D, Momparleur L, Dionne, JKB and Ayoub J: Pilot phase I-II study on aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8: 358-368, 1997.
19. Silverman L, Demakos E, Peterson B, Odchimar-Ressig R, Nelson D, Kornblith A, Stone R, Holland J, Powell B, DeCastro C, Ellerton J, Larson R, Schiffer C and Holland J: A randomized controlled trial of subcutaneous azacytidine (azaC) in patients with the myelodysplastic sundrome (MDS): a study of the cancer and leukemia group B. Am Soc Clin Oncol Proc 17: 14a, 1998.